IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer(NSCLC)
Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is an open label, multicenter, phase Ib study evaluating IBI310 (anti-CTLA-4) in
combination with Sintilimab in patients with advanced, recurrent or metastatic non-small-cell
lung cancer(NSCLC)